SCHEMBL13837185

SCHEMBL13837185

CC(=O)c1cn(CC(=O)OC(=O)C(F)(F)F)c2cnc(C)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CFD P00746 5/20 0.41
▸ SMN1; SMN2 Q16637 7/20 0.36
▸ LMNA P02545 4/20 0.36
▸ RXFP1 Q9HBX9 3/20 0.36
▸ HTT P42858 3/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ CYP2D6 P10635 2/20 0.35
▸ CYP2C9 P11712 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ GAA P10253 1/20 0.34
▸ CREBBP Q92793 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ RAB9A P51151 2/20 0.33
▸ IDO1 P14902 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ STAT3 P40763 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL13837183 0.84 KDM4E (0.43) CFDSMN1; SMN2LMNARXFP1HTT
SCHEMBL12480792 0.81 LMNA (0.44) CFDSMN1; SMN2LMNARXFP1HTT
SCHEMBL13967351 0.80 CFD (0.44) CFDSMN1; SMN2LMNARXFP1HTT
SCHEMBL13837586 0.78 LMNA (0.44) CFDSMN1; SMN2LMNAHTTGAA
SCHEMBL13837153 0.76 CFD (0.43) CFDSMN1; SMN2KMT2AALDH1A1TSHR
SCHEMBL12479754 0.74 CFD (0.50) CFD
SCHEMBL19208832 0.72 LMNA (0.46) SMN1; SMN2LMNARXFP1HTTCYP3A4
SCHEMBL15542145 0.71 CFD (0.41) CFDSMN1; SMN2HTTCYP3A4CYP2D6
SCHEMBL12481207 0.70 CFD (0.41) CFDSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL13837037 0.70 KMT2A (0.45) CFDLMNACYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661433-B1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2017-08-16 — — EP disclosed
US-9085555-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2015-07-21 — — US disclosed
CN-103402996-A Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD) NOVARTIS AG 2013-11-20 — — CN disclosed
US-20120295884-A1 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2012-11-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295884-A1 Complement pathway modulators and uses thereof C5, C3AR1, C9 CFD 9/4885SMN1; SMN2 3547/4885LMNA 3778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback